Commonwealth Diagnostics Intl, Inc.

Commonwealth Diagnostics International (CDI) is a CLIA-certified clinical laboratory and diagnostic solutions provider specializing in hydrogen and methane breath testing for functional gastrointestinal disorders. CDI manufactures and distributes non-invasive, at-home breath test kits for the diagnosis of small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), and carbohydrate malabsorption disorders (fructose, lactose, and sucrose malabsorption) in both adult and pediatric populations. The company operates proprietary gas chromatography instrumentation for test analysis and offers MyGI Gateway, a cloud-based digital platform for centralized management of patient orders, data, and results reporting. CDI delivers test results within one business day and maintains ISO 13485 certification, FDA registration, CE marking, and SAM.gov registration. The company serves gastroenterology practices, functional medicine providers, naturopathic doctors, and direct-to-consumer patients. CDI emphasizes clinically validated testing methods, peer-reviewed evidence, rapid turnaround, insurance coverage coordination (Medicare and commercial), and comprehensive provider and patient support resources including educational content, clinical guidelines, and billing assistance. The laboratory is located in Salem, Massachusetts.